Large pharmaceutical companies have promised to invest more than $370 billion over the next five years in the U.S., driven by Trump’s threat of pharma-specific tariffs.
The agency cited “significant violations” of current Good Manufacturing Practice regulations for finished pharmaceuticals at Novo Nordisk’s Bloomington facility.
The Swiss contract development and manufacturing organization is the only CDMO with available large-scale U.S. mammalian capacity, according to William Blair analysts.
Implementing autonomous manufacturing requires an expanded approach to continuous manufacturing that combines orchestration, seamless data flow, robotics, and intelligent simulation...
Contract research, development, and manufacturing organization Sai Life Sciences sees growing demand from Big Pharma clients diversifying away from China.
Following major investments in peptide and API capacities, CEO Thomas Loewald discusses supply chain localization, biotech funding trends, and scaling to meet demand.
The industry requires local resilience and flexibility in a complex global landscape, according to separate reports from consulting firms Deloitte and West Monroe.
The Huntsville active pharmaceutical ingredient site will produce small molecule synthetic and peptide medicines, including Lilly's oral GLP-1 orforglipron.
The company earlier this year purchased a Catalent drug product manufacturing facility in Somerset, New Jersey, securing its first footprint in the United States.
The deal is a win for Britain’s beleaguered pharma sector and comes after President Trump threatened to impose 100% tariffs on branded drugs imported to the U.S.
Report finds 40 states and Puerto Rico are offering sales and tax exemptions to lower costs for new biomanufacturing and research and development facilities.
The pharmaceutical company is investing in a greenfield project as it looks to resolve ongoing FDA compliance issues at three existing Indian facilities.
In a pharma trade deal between President Trump and British Prime Minister Starmer, the U.K.’s National Health Service will pay 25% more for innovative medicines.
With pledges of more than $370 billion over the next five years, the eastern U.S. remains the primary investment region, finds DPR Construction’s Q4 2025 report.
Agilent Technologies CEO Padraig McDonnell contends that Biovectra’s capabilities are well-positioned to take advantage of GLP-1s and their strong growth potential.
The company’s reduction in workforce comes as it continues to focus on implementing “innovative” manufacturing technologies to better produce novel drugs.
The company is adding to a biologics manufacturing site in Frederick and building a facility in Gaithersburg for the development and supply of drugs for clinical trials.
This week, the industry saw a flurry of pharma manufacturing investment announcements as companies continue to onshore production in the United States.
The Swiss pharma giant intends to nearly double its operational footprint in the state to more than 700,000 square feet between the existing campus and new facilities.
The tariff rate on pharmaceuticals imported from Switzerland and Liechtenstein to the United States is in line with Trump’s trade agreement in late July with the EU.
The adoption of artificial intelligence has evolved with investment shifting from monitoring to predictive intelligence, according to the 2025 LogiPharma AI Report.
Eli Lilly and Novo Nordisk are latest to accept quid pro quo of Most Favored Nation drug pricing and onshoring of pharmaceutical manufacturing for tariff exemptions.
The CDMO, which specializes in sterile injectables, is investing in a dual-continent expansion strategy at its sites in Bloomington, Indiana and Halle/Westfalen, Germany.
Raleigh-Cary and Durham-Chapel Hill secured the first and third spots, respectively, as the nation’s most competitive markets for the production of therapeutic biologics.
While Big Pharma has the resources to invest in domestic production, smaller biotech companies increasingly rely on contract manufacturers who need help.